Benitec Biopharma's stock has surged 205%, despite being a loss-making company. Analyzing its cash burn rate and runway, it seems relatively promising. However, potential dilution and risks should be considered by shareholders.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing